Results 21 to 30 of about 482,975 (382)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Journal of Thrombosis and Haemostasis, 2020
A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous ...
N. Tang, Huan Bai, Xing Chen, Jiale Gong, Dengju Li, Ziyong Sun   +5 more
semanticscholar   +1 more source

Anticoagulant rodenticides on our public and community lands: spatial distribution of exposure and poisoning of a rare forest carnivore. [PDF]

, 2012
Anticoagulant rodenticide (AR) poisoning has emerged as a significant concern for conservation and management of non-target wildlife. The purpose for these toxicants is to suppress pest populations in agricultural or urban settings.
Barrett, Reginald H, Clifford, Deana L, Gabriel, Mourad W, Higley, J Mark, Keller, Stefan M, Matthews, Sean M, Poppenga, Robert, Purcell, Kathryn, Sacks, Benjamin N, Sweitzer, Rick A, Thompson, Craig, Wengert, Greta M, Woods, Leslie W   +12 more
core   +9 more sources

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions.
Ashley Chen, E. Stecker, Bruce A Warden
semanticscholar   +1 more source

Sterilization of heparinized Cuprophan hemodialysis membranes [PDF]

, 1996
The effects of sterilization of dry heparinized Cuprophan hemodialysis membranes by means of ethylene oxide (EtO) exposure, gamma irradiation, or steam on the anticoagulant activity and chemical characteristics of immobilized heparin and the permeability
Engbers, G.H.M., Feijen, J., Hinrichs, W.L.J., Hoopen, H.W.M. ten   +3 more
core   +15 more sources

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

New England Journal of Medicine, 2020
Prolonged aPTT in Patients with Covid-19 In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time.
L. Bowles, S. Platton, Nada Yartey, Minal Dave, Kurtis Lee, D. Hart, Vickie MacDonald, Laura Green, S. Sivapalaratnam, K. Pasi, P. Maccallum   +10 more
semanticscholar   +1 more source

Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis

Seminars in Thrombosis and Hemostasis, 2021
We conducted a systematic review and a meta-analysis to assess the association of anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients.
R. Parisi, S. Costanzo, A. Di Castelnuovo, G. de Gaetano, M. Donati, L. Iacoviello   +5 more
semanticscholar   +1 more source

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Journal of Thrombosis and Thrombolysis, 2020
Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar
G. Barnes, Allison E. Burnett, Arthur L. Allen, Marilyn Blumenstein, N. Clark, A. Cuker, William E Dager, S. Deitelzweig, S. Ellsworth, D. Garcia, S. Kaatz, Tracy Minichiello   +11 more
semanticscholar   +1 more source

Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer. [PDF]

Front Neurol
Kielkopf MC, Göcmen J, Venzin SB, Steinauer F, Branca M, Boronylo A, Göldlin MB, Kaesmacher J, Mujanovic A, Costamagna G, Meinel TR, Seiffge DJ, Bücke P, Heldner MR, Liberman AL, Kamel H, Fischer U, Arnold M, Pabst T, Berger MD, Jung S, Scutelnic A, Navi BB, Beyeler M.   +23 more
europepmc   +3 more sources

Comparison of circuit patency and exchange rates between the original and generic versions of nafamostat mesylate in critically ill adults receiving continuous renal replacement therapy [PDF]

Kosin Medical Journal, 2023
Background Nafamostat mesylate is widely used as an anticoagulant in continuous renal replacement therapy (CRRT). The generic versions of nafamostat mesylate have identical main components to the original product.
Sujung Heo, Yanghyeon Kim, Nagyeom Lee, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim   +6 more
doaj   +1 more source

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis, 2020
This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as well as interpretation of results for clinicians. The main changes in how to test for LA compared with the International Society on Thrombosis and Haemostasis ...
K. Devreese, P. D. de Groot, B. de Laat, D. Erkan, E. Favaloro, I. Mackie, M. Martinuzzo, T. Ortel, V. Pengo, J. Rand, A. Tripodi, D. Wahl, H. Cohen   +12 more
semanticscholar   +1 more source